| Literature DB >> 34799609 |
Anees Ur Rehman1,2, Sohail Ayaz Muhammad3, Zermina Tasleem4, Alyaa Alsaedi5, Mamoona Dar6, Muhammad Omer Iqbal7, Muhammad Fawad Rasool8, Shahid Shah9, Ghulam Abbas9, Sadia Shakeel10, Khezar Hayat11.
Abstract
Chronic obstructive pulmonary disease (COPD) is associated with substantial humanistic and socioeconomic burden on patients and their caregivers. COPD is expected to be 7th leading cause of disease burden till 2030. The objective of the current study was to assess the humanistic and socioeconomic burden of COPD patients and their caregivers in Malaysia. The burden includes the cost of management of COPD, QOL of COPD patients and their caregivers, work productivity and activity impairment of COPD patients and their caregivers due to COPD. One hundred and fifty COPD patients and their caregivers from the chest clinic of Penang Hospital were included in the study from August 2018 to August 2019. Caregiving cost was estimated using the replacement cost approach, while humanistic and social burden was assessed with the help of health status questionnaires. Overall, 64.66% and 7.1% of COPD patients reported to depend on informal caregivers and professional caregivers respectively. COPD patients reported dyspnoea score as 2.31 (1.31), EQ-5D-5L utility index 0.57 (0.23), CCI 2.3 (1.4), SGRQ-C 49.23 (18.61), productivity loss 31.87% and activity impairment 17.42%. Caregivers reported dyspnoea score as 0.72 (0.14), EQ-5D-5L utility index 0.57 (0.23), productivity loss 7.19% and social activity limitation as 21.63% due to taking care of COPD patients. In addition to the huge direct cost of management, COPD is also associated with substantial burden on society in terms of compromised quality of life, reduced efficiency at the workplace, activity impairment and caregiver burden.Entities:
Mesh:
Year: 2021 PMID: 34799609 PMCID: PMC8604899 DOI: 10.1038/s41598-021-01551-5
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Humanistic, economic and societal burden due to COPD on patients and their caregivers.
Sociodemographic and clinical characteristics of the COPD patients and their caregivers.
| COPD patients | COPD caregivers | p value | |
|---|---|---|---|
| No. of patients (%) | 150 | 127 | – |
| BMI | 24.14 (4.67) kg/m2 | 20.97 (3.19) kg/m2 | < 0.01 |
| Male | 104 (69.33%) | 48 (37.79%) | 0.12 |
| Mean age | 61.56 (8.3) | 49.38 (8.5) | < 0.01 |
| Malay | 37 (24.66%) | 32 (25.91%) | 0.54 |
| Chinese | 65 (43.33%) | 62 (48.81%) | 0.67 |
| Tamil | 44 (29.33%) | 31 (24.40%) | 0.34 |
| Others | 4 (2.66%) | 2 (2.06%) | 0.09 |
| Retired | 29 (19.33%) | 14 (14.43%) | 0.25 |
| Full time | 96 (64.0%) | 95 (74.80%) | 0.12 |
| Part-time | 25 (16.67%) | 18 (14.17%) | 0.67 |
| Current smokers | 19 (12.66%) | 49 (38.58%) | < 0.01 |
| Ex-smoker | 107 (71.33%) | 18 (14.17%) | < 0.01 |
| Never smoker | 24 (16%) | 60 (47.24%) | < 0.01 |
| Years with COPD | 6.7 (5.23) | – | |
| CCI | 2.3 (1.4) | 0.52 (0.35) | < 0.001 |
| FEV1% | 53.74 (12.84) | ||
| FEV1/FVC | 51.36 (11.14) | ||
| LABA | 103 (68.66%) | ||
| LAMA | 94 (62.66%) | ||
| ICS | 47 (31.33%) | ||
| 6MWT in meters | 421.5 (65.28) | ||
| GOLD grade I | 25 (16.60) | ||
| GOLD grade II | 44 (29.33) | ||
| GOLD grade III | 53 (35.33 | ||
| GOLD grade IV | 28 (18.67) | ||
| Hospitalization | 46 (30.67%) | ||
| Exacerbation per year | 1.27 (1.4) | ||
| Hospital stay days | 4.9 (4.8) | ||
Results were displayed as mean (standard deviation) and number (percentage) unless otherwise stated.
BMI, Body mass index in kg/m2; COPD, Chronic obstructive pulmonary disease; CCI, Charlson comorbidity index; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; FEV1%, % predicted FEV1; GOLD 1, FEV1 ≥ 80% predicted; GOLD II, FEV1 50% to 80% predicted; GOLD III, FEV1 30% to 50% predicted; GOLD IV, FEV1 < 30% predicted; ICS; Inhaled Corticosteroids; LABA, long-acting beta agonist; LAMA, long acting muscarinic antagonist.
Societal and economic burden of COPD patients and their caregivers.
| Personnel cost | $52.77 (24.49) |
| Pharmacy cost | $370.80 (216.5) |
| Procedure’s cost | $13.30 (7.4) |
| X-ray cost | $6.80 (2.05) |
| Spirometry cost | $4.58 (2.61) |
| Laboratory cost | $14.18 (3.03) |
| Inpatient cost | $103.09 (58.59) |
| Othersa | $16.42 (10.34) |
| Direct non-medical cost | $8.57 (3.71) |
| Total direct cost | US$586.78 |
| Informal caregiver costb | $347.63 (157.38) |
| Professional caregiver costc | $1001.96 (337.42) |
| Total caregiving cost | US$1349.59 |
| COPD patients | $1699.76 (627.26) |
| Caregivers | $217.92(87.72) |
| Total indirect cost | US$1917.68 |
All costs in US$ (United States dollar); 1US$ = 4.13MYR on September 18, 2019; mean (standard deviation); COPD, Chronic obstructive pulmonary disease.
aOthers, (cleaning, electricity, communication, building maintenance, and depreciation cost).
b64.66% of COPD patients were depending on informal caregivers.
c7.1% of COPD patients utilised professional healthcare services at home.
Indirect cost of patients and their attendants.
| COPD patients | COPD caregivers | p value | |
|---|---|---|---|
| Currently employed | 12 (80.67%) | 113 (88.97%) | 0.42 |
| Absenteeism %a | 26.37% (7.12) | 4.17% | < 0.01 |
| Absenteeism due to other reasons | 5.46% (1.86) | 11.34%(4.28) | < 0.01 |
| Presenteeism % | 31.87% (9.98) | 7.19% (2.1) | < 0.01 |
| Activity impairment %b | 27.42% (6.59) | 21.63% (8.5) | 0.17 |
All results displayed as mean (standard deviation) unless otherwise stated; absenteeism, work time lost due to COPD or taking care of COPD patient; activity impairment, restriction in daily activities; presenteeism, reduced productivity while at work due to COPD or taking care of COPD patients.
aAbsenteeism % was calculated by dividing missing hours with total working hours.
bFor caregivers activity limitation was considered as social activity limitation due to taking care of COPD patient.
Humanistic burden due to COPD on patients and their caregivers.
| COPD patients | Caregivers | p value | |
|---|---|---|---|
| mMRC dysponea | 2.31 (1.31) | 0.72 (0.14) | < 0.01 |
| EQ-5D-5L UI | 0.57 (0.23) | 0.76 (0.36) | < 0.01 |
| EQ-VAS | 53.24 (17.30) | 85.64 (14.52) | < 0.01 |
| SGRQ-C symptom score | 53.44 (19.98) | ||
| SGRQ-C activity score | 48.43 (18.78) | ||
| SGRQ-C impact score | 43.37 (20.71) | ||
| SGRQ-C total | 49.23 (18.61) | ||
All results displayed as mean (standard deviation) unless otherwise stated.
EQ-5D-5L, European quality of life 5-Dimension 5-Level questionnaire; EQ-UI, EQ-5D-5L utility index; EQ-VAS, EQ-5D-5L vertical visual analogue scale; mMRC dyspnoea, Modified medical research council dyspnoea scale; SGRQ-C, Malaysian version of St. George’s Respiratory COPD specific questionnaire.